Psychedelics—psychoactive substances that have characteristic effects on perception, cognition and mood—are attracting renewed clinical and policy attention for their potential to treat a range of conditions. Various ethical tensions are present in psychedelic clinical trials due to several characteristics of psychedelics and the psychedelic experience, including acute alterations of...
Some investigational compounds exist in both regulated clinical pipelines and unregulated street or online markets. Ketamine, psychedelics and cannabis are all under active clinical investigation while remaining accessible, in unregulated form, through illicit channels without clinician oversight. We propose the term parallel-access compounds for this category and argue that it deserves...
Psychedelic treatments hold significant therapeutic promise for various psychiatric conditions. However, their unique therapeutic setting with psychedelic substance dosing sessions presents a particular ethical issue concerning patient autonomy. This article explores the ethics of limiting personal autonomy and freedom of movement during dosing sessions due to concerns for physical safety....
The application for MDMA-assisted therapy (MDMA-AT) and its rejection by the FDA in 2024 prompted a debate about ethical aspects in drug regulation. This paper examines central issues raised in that debate through the lens of human rights, especially the right to health. It argues that drug approval decisions must take into account the multipolar constellation of and dependencies between...